The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform
M C Khan - One of the best experts on this subject based on the ideXlab platform.
-
inadequate treatment response to des enkephalin Gamma Endorphin compared with thioridazine and placebo in schizophrenia
Acta Psychiatrica Scandinavica, 1992Co-Authors: S A Montgomery, Steven R. Hirsch, M Green, Ranan Rimon, L Heikkila, R Forsstrom, C Hallstrom, H Hippius, R Naber, M C KhanAbstract:The possibility of an involvement of peptidergic systems in schizophrenia has been under investigation for a number of years. Studies of the efficacy of des-tyr-Gamma-Endorphin were equivocal; more recent studies with des-enkephalin-Gamma-Endorphin have reported some activity but the peptide has only been investigated as an adjunct to neuroleptic medication, apart from one very small active reference comparator study. In the multicentre study reported here, 96 patients suffering from schizophrenia (DSM-III with a current exacerbation if chronic) were allocated randomly to double-blind treatment with either des-enkephalin-Gamma-Endorphin (DE-Gamma-E) (Org 5878) 10 mg given as a once daily intramuscular injection for 4 weeks, thioridazine 400 mg orally in 2 divided doses or placebo using a double-dummy technique to preserve blindness. There was a significant advantage for thioridazine compared with placebo registered on all measures at weeks 3 and 4. There was no difference between DE-Gamma-E and placebo. There was a significant difference between thioridazine and DE-Gamma-E at weeks 3 and 4 registered on the MSS and at week 3 registered on the BPRS. The lack of efficacy of DE-Gamma-E suggests that the theories that the Endorphins have an important role in schizophrenia have to be revised. The need for well designed placebo controlled studies for assessing efficacy in schizophrenia is emphasized.
Van Amerongen P - One of the best experts on this subject based on the ideXlab platform.
-
des enkephalin Gamma Endorphin in the treatment of schizophrenia
International Clinical Psychopharmacology, 1990Co-Authors: J M Azorin, A Blum, J Charbaut, M Escande, F Granier, J P Huber, J Y Metzger, H Richou, A Sitsen, Van Amerongen PAbstract:: Ninety-three patients with an exacerbation of chronic schizophrenia were included in a 4 week trial comparing placebo with 1, 3 and 10 mg des-enkephalin-Gamma-Endorphin (DE Gamma E; beta-lipotrophin 66-77; Org 5878) per day (i.m.). Maintenance antipsychotic and other medications were continued unchanged. Treatment effects were assessed by means of the Comprehensive Psychopathological Rating Scale--subscale schizophrenia (CPRS-S), Brief Psychiatric Rating Scale (BPRS) and Global Assessment Scale (GAS) rating scales at weekly intervals. Safety data, i.e. laboratory investigations, vital signs and ECG recordings, were assessed before and during the trial. Side-effects were evaluated by means of a Record of Symptoms Emerging. Sixty-eight patients completed the trial, the reason for drop-out mainly being inadequate treatment effects and refusal of medication administration. One patient violated the protocol. After 4 weeks of treatment the mean CPRS-S score of the group receiving 10 mg DE Gamma E daily had decreased statistically significantly more than the corresponding score of the placebo group (p less than 0.01). The same trend was apparent with BPRS (p = 0.08) and GAS (p greater than 0.1) scores. Therefore, the study should be considered inconclusive. No clinically relevant side-effects attributable to DE Gamma E were observed.
S A Montgomery - One of the best experts on this subject based on the ideXlab platform.
-
inadequate treatment response to des enkephalin Gamma Endorphin compared with thioridazine and placebo in schizophrenia
Acta Psychiatrica Scandinavica, 1992Co-Authors: S A Montgomery, Steven R. Hirsch, M Green, Ranan Rimon, L Heikkila, R Forsstrom, C Hallstrom, H Hippius, R Naber, M C KhanAbstract:The possibility of an involvement of peptidergic systems in schizophrenia has been under investigation for a number of years. Studies of the efficacy of des-tyr-Gamma-Endorphin were equivocal; more recent studies with des-enkephalin-Gamma-Endorphin have reported some activity but the peptide has only been investigated as an adjunct to neuroleptic medication, apart from one very small active reference comparator study. In the multicentre study reported here, 96 patients suffering from schizophrenia (DSM-III with a current exacerbation if chronic) were allocated randomly to double-blind treatment with either des-enkephalin-Gamma-Endorphin (DE-Gamma-E) (Org 5878) 10 mg given as a once daily intramuscular injection for 4 weeks, thioridazine 400 mg orally in 2 divided doses or placebo using a double-dummy technique to preserve blindness. There was a significant advantage for thioridazine compared with placebo registered on all measures at weeks 3 and 4. There was no difference between DE-Gamma-E and placebo. There was a significant difference between thioridazine and DE-Gamma-E at weeks 3 and 4 registered on the MSS and at week 3 registered on the BPRS. The lack of efficacy of DE-Gamma-E suggests that the theories that the Endorphins have an important role in schizophrenia have to be revised. The need for well designed placebo controlled studies for assessing efficacy in schizophrenia is emphasized.
J M Azorin - One of the best experts on this subject based on the ideXlab platform.
-
des enkephalin Gamma Endorphin in the treatment of schizophrenia
International Clinical Psychopharmacology, 1990Co-Authors: J M Azorin, A Blum, J Charbaut, M Escande, F Granier, J P Huber, J Y Metzger, H Richou, A Sitsen, Van Amerongen PAbstract:: Ninety-three patients with an exacerbation of chronic schizophrenia were included in a 4 week trial comparing placebo with 1, 3 and 10 mg des-enkephalin-Gamma-Endorphin (DE Gamma E; beta-lipotrophin 66-77; Org 5878) per day (i.m.). Maintenance antipsychotic and other medications were continued unchanged. Treatment effects were assessed by means of the Comprehensive Psychopathological Rating Scale--subscale schizophrenia (CPRS-S), Brief Psychiatric Rating Scale (BPRS) and Global Assessment Scale (GAS) rating scales at weekly intervals. Safety data, i.e. laboratory investigations, vital signs and ECG recordings, were assessed before and during the trial. Side-effects were evaluated by means of a Record of Symptoms Emerging. Sixty-eight patients completed the trial, the reason for drop-out mainly being inadequate treatment effects and refusal of medication administration. One patient violated the protocol. After 4 weeks of treatment the mean CPRS-S score of the group receiving 10 mg DE Gamma E daily had decreased statistically significantly more than the corresponding score of the placebo group (p less than 0.01). The same trend was apparent with BPRS (p = 0.08) and GAS (p greater than 0.1) scores. Therefore, the study should be considered inconclusive. No clinically relevant side-effects attributable to DE Gamma E were observed.
Steven R. Hirsch - One of the best experts on this subject based on the ideXlab platform.
-
inadequate treatment response to des enkephalin Gamma Endorphin compared with thioridazine and placebo in schizophrenia
Acta Psychiatrica Scandinavica, 1992Co-Authors: S A Montgomery, Steven R. Hirsch, M Green, Ranan Rimon, L Heikkila, R Forsstrom, C Hallstrom, H Hippius, R Naber, M C KhanAbstract:The possibility of an involvement of peptidergic systems in schizophrenia has been under investigation for a number of years. Studies of the efficacy of des-tyr-Gamma-Endorphin were equivocal; more recent studies with des-enkephalin-Gamma-Endorphin have reported some activity but the peptide has only been investigated as an adjunct to neuroleptic medication, apart from one very small active reference comparator study. In the multicentre study reported here, 96 patients suffering from schizophrenia (DSM-III with a current exacerbation if chronic) were allocated randomly to double-blind treatment with either des-enkephalin-Gamma-Endorphin (DE-Gamma-E) (Org 5878) 10 mg given as a once daily intramuscular injection for 4 weeks, thioridazine 400 mg orally in 2 divided doses or placebo using a double-dummy technique to preserve blindness. There was a significant advantage for thioridazine compared with placebo registered on all measures at weeks 3 and 4. There was no difference between DE-Gamma-E and placebo. There was a significant difference between thioridazine and DE-Gamma-E at weeks 3 and 4 registered on the MSS and at week 3 registered on the BPRS. The lack of efficacy of DE-Gamma-E suggests that the theories that the Endorphins have an important role in schizophrenia have to be revised. The need for well designed placebo controlled studies for assessing efficacy in schizophrenia is emphasized.
